XKH001 injection for reducing COPD flare-ups
Part of Lungs & breathing clinical trials.
This trial tests a new injection called XKH001 to see if it can reduce COPD flare-ups and improve lung function. It may help people with moderate to severe COPD who have had recent flare-ups despite using standard inhaled medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 80 years old.
- You have been diagnosed with COPD for at least 1 year.
- You are a current or former smoker with at least 10 pack-years of smoking history (that's about 20 cigarettes a day for 10 years).
- You have had at least 2 COPD flare-ups needing steroids or antibiotics, or at least one flare-up requiring a hospital stay in the past year.
- You are currently on a stable inhaled COPD medication (like a combination inhaler) for at least 3 months, with no dose changes for 1 month.
- Your blood test shows a certain type of white blood cell (eosinophils) at 150 or higher.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new approach to reduce flare-ups (sudden worsening of symptoms) in people with COPD. If you've had frequent flare-ups, this trial may help you manage your condition better.
This trial tests an injection called RC1416 for people with moderate-to-severe COPD who still have flare-ups despite using triple inhaler therapy. It may help reduce those flare-ups and improve breathing.
This study tests a new injectable medicine called JKN2401 to see if it can reduce COPD flare-ups and improve breathing for people with moderate-to-severe COPD. It is a phase 3 trial, which means it's a late-stage test to confirm the treatment works and is safe.
This trial tests two forms of a new medication (HSK39004) in people with COPD. The goal is to see if they help improve breathing and are safe. Eligible participants must be between 40 and 80, have moderate to severe COPD, and be able to stop other COPD treatments during the study.
This study tests whether a new inhaled medication called HSK39004 can help people with COPD breathe better and reduce shortness of breath. You'll receive either the medication or a placebo (inactive powder) and be monitored for safety and effectiveness.
This trial tests a new medicine called CM512 (given as an injection) to see if it can reduce COPD flare-ups and improve lung function. It is for people with moderate-to-severe COPD who have had recent flare-ups despite using inhalers.
Hear when a new COPD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.